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Epidermolysis bullosa acquisita (EBA) is an acquired, 
autoimmune blistering disorder caused by autoanti-
body production against type VII collagen. The aim of 
this study was to examine the clinical types, treatments, 
and outcomes of 30 patients with EBA. In our cohort, 
the median age of onset was 44.0 years, with a similar 
incidence for both genders (46.7% male, 53.3% female). 
The majority of patients had classic type (36.7%) and 
bullous pemphigoid (BP)-like type (46.7%) EBA. The re-
maining patients had mucous membrane pemphigoid-li-
ke (6.7%), Brunsting-Perry pemphigoid-like (6.7%), and 
linear IgA bullous dermatosis-like type (3.3%) EBA. All 
patients were treated initially with a combination of met-
hylprednisolone, dapsone and colchicine. No significant 
differences in time to remission were identified between 
patients with classic vs. BP-like EBA. In a second subset 
analysis of 19 patients, a group treated with high-dose 
(> 8 mg) methylprednisolone achieved remission earlier 
(median time to remission: 3 months) than a group trea-
ted with low-dose (≤ 8 mg) methylprednisolone (median 
time to remission: 12 months), irrespective of clinical 
type (p = 0.003). Key words: epidermolysis bullosa acqui-
sita; retrospective study, clinical study remission.
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Epidermolysis bullosa acquisita (EBA) is a blistering 
disease associated with autoantibody production against 
type VII collagen, the major component of the anchoring 
fibrils that connect the basement membrane zone to the 
papillary dermis (1, 2). Although the exact pathophy-
siologic process in EBA remains unclear, circulating 
autoantibodies against type VII collagen in patients with 
EBA ultimately result in subepidermal blister formation 
with concomitant inflammation, milia and scarring (3). 
The mucocutaneous lesions of EBA can be quite 
varied and mimic other types of autoimmune bullous 
disease. Currently, 5 clinical presentations of EBA have 
been identified: (i) classic (4); (ii) bullous pemphigoid 
(BP)-like (5); (iii) mucous membrane pemphigoid 
(MMP)-like (6); (iv) Brunsting-Perry pemphigoid-like 
(7); and (v) linear lgA bullous dermatosis (LAD)-like 
type (Table I) (8). The classic form of EBA is a non-
inflammatory mechanobullous disease primarily in-
volving trauma-prone areas of skin, such as the hands, 
elbows, knees, and feet, and in some cases the oral 
mucosa. BP-like EBA is an inflammatory vesiculobul-
lous eruption that mainly involves the trunk, central 
body, extremities, skin folds and, in some cases, the oral 
mucosa. Individuals with disease that primarily affects 
mucosal surfaces are defined as having the MMP-like 
EBA, while Brunsting-Perry pemphigoid-like EBA is 
a chronic, recurrent blistering disease confined to the 
head and neck. LAD-like type presents with linear IgA 
deposits in the basement membrane zone that can be 
observed with direct immunofluorescence (9). 
EBA is a chronic disease that is often refractory to 
many treatment modalities. Generally, patients with EBA 
require supportive care, such as wound management and 
education regarding trauma prevention, especially in 
individuals with the classic mechanobullous type of the 
disease. However, while some patients with EBA respond 
well to treatment with dapsone (10), colchicines (11) 
and cyclosporine, many patients, particularly those with 
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Table I. Clinical types of epidermolysis bullosa acquisita (EBA)
Clinical type
Classic EBA A non-inflammatory mechanobullous disease primarily involving trauma-prone areas of skin, such as the 
hands, elbows, knees, and feet, and in some cases the oral mucosa 
Bullous pemphigoid-like type EBA An inflammatory vesiculobullous eruption that mainly involves the trunk, central body, extremities, skin 
folds, and in some cases the oral mucosa
Mucous membrane pemphigoid-like type EBA A disease that primarily affects mucosal surfaces
Brunsting-Perry pemphigoid-like type EBA A chronic, recurrent blistering disease confined to the head and neck
Linear IgA dermatosis-like type EBA A disease that presents with linear IgA deposits in the basement membrane zone that can be observed 
with direct immunofluorescence
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classic mechanobullous disease, respond poorly to syste-
mic corticosteroids and immunosuppressive agents (e.g. 
azathioprine, methotrexate and cyclophosphamide) (9). 
More recently, both extracorporeal photochemotherapy 
(12) and intravenous immunoglobulin (13) have also been 
reported to be effective in some patients with EBA.
To date, only a few clinical studies of EBA have been 
conducted, presumably because EBA is a relatively rare 
disease (14). No significant etiologic factors for EBA 
have been identified in the previous clinical studies, 
although one study did report an association between 
the HLA-DR2 allele and EBA (15). Most estimates indi-
cate the prevalence of EBA to be 1 case per 1.3 million 
people in Germany and 4 cases per 3.6 million people 
in France (16, 17). Here, we conducted a retrospective 
clinical analysis of 30 patients with EBA to determine 
the clinical manifestations of the disease and evaluate 
treatment outcomes. Statistical analyses were employed 
to evaluate any differences in treatment outcome bet-
ween classic and BP-like type EBA and to identify any 
correlations between systemic corticosteroid dose and 
therapeutic efficacy.
MATERIALS AND METHODS
All data for this study were collected retrospectively from the 
medical records of 30 patients diagnosed with EBA over a 16-
year period (1994–2009) in the Department of Dermatology of 
Gangnam Severance Hospital, Seoul, Korea. In all individuals, 
diagnosis was made by clinical and histologic features, and 
later confirmed through immunofluorescence and immunoblot 
analyses (Table II). In the present study, we evaluate age of 
onset, clinical type, duration of follow-up, medical treatments, 
comorbidities, and time to remission.
Here, we used the definitions of remission for EBA by modi-
fication of definition of remission for pemphigus suggested by 
the International Pemphigus Committee (18). “Complete remis-
sion (CR) off therapy” was defined as the absence of new and/
or established lesions for at least two months with out treatment. 
“Complete remission on therapy” was defined as the absence of 
new lesions while the patient is receiving minimal therapy. “Mi-
nimal therapy” was defined as less than or equal to 8 mg/day of 
methylprednisolone with or without adjuvant therapy including 
dapsone and colchicines for at least two months. “Partial remis-
sion (PR) off therapy” was defined as the presence of transient 
new lesions that heal within one week without treatment for at 
least two months. “Partial remission on minimal therapy” was 
defined as the presence of transient new lesions that heal within 
one week while the patient is receiving minimal therapy. 
The treatment protocol for patients with EBA is described 
below. Initially, all patients were treated with combination 
therapy of low-dose methylprednisolone, dapsone and col-
chicine. Patients with mild clinical features (less than 10% 
of body involvement) initially were prescribed ≤ 8 mg/day of 
methylprednisolone, while patients with severe clinical fea-
tures (more than 10% of body involvement) were prescribed 
> 8 mg/day of methylprednisolone. Systemic corticosteroid 
dosage was later adjusted by therapeutic response. For dapsone, 
patients were initially prescribed a dose of 25 mg/day, which 
Table II. Patient characteristics 
Patient No. Sex/age (years)a Clinical type DIF Salt-split DIF Salt-split IIF IIF Western blot
1 F/78 1 IgG, IgA, C3 Dermal Dermal 1:40 ND
2 F/24 1 IgG, IgA, C3 Dermal Negative 0 ND
3 F/37 1 IgG, IgA Dermal Negative 0 ND
4 F/66 1 IgG, C3 Dermal Dermal 1:20 Positive
5 F/68 1 IgG, C3 Dermal Dermal 1:160 ND
6 F/41 1 Negative ND Dermal 1:40 Positive
7 M/59 1 Negative ND Dermal 1:160 Positive
8 F/83 1 C3 Dermal Dermal 1:5 Positive
9 M/73 1 IgG Dermal Dermal 1:10 Positive
10 M/60 1 IgG Dermal Negative 0 Positive
11 M/45 1 IgG, IgA Dermal Negative 0 ND
12 F/74 2 IgG, IgA, C3 Dermal Negative 0 ND
13 F/45 2 IgG, IgA, IgM, C3 Dermal Negative 0 Positive
14 F/55 2 IgG, IgA Dermal Negative 0 ND
15 F/35 2 IgG, C3 Dermal Dermal 1:20 ND
16 M/72 2 IgG, C3 Dermal Dermal 1:640 Positive
17 M/39 2 IgG, IgA, C3 Dermal Dermal 1:160 Positive
18 M/52 2 IgG, C3 Dermal Dermal 1:40 ND
19 M/31 2 IgG, IgA, C3 Dermal Dermal 1:16 Positive
20 F/47 2 IgG, C3 Dermal Negative 0 Negative
21 F/39 2 IgG, IgA, C3 Dermal Negative 0 ND
22 F/67 2 IgG, C3 Dermal Dermal 1:640 Positive
23 M/35 2 IgG, C3 Dermal Dermal 1:80 ND
24 M/70 2 IgG, IgA, C3 Dermal Negative 0 ND
25 M/55 2 IgG, C3 Dermal Dermal 1:20 Positive
26 F/66 3 Negative ND Dermal 1:320 Positive
27 M/66 3 IgG, C3 Dermal Negative 0 Negative
28 M/55 4 IgG, C3 Demral Negative 0 Negative
29 F/27 4 IgG, C3 Dermal Dermal 1:160 ND
30 M/29 5 IgA Dermal Negative 0 ND
aAge at time of writing. Clinical type: 1 = classic type; 2 = bullous pemphigoid-like type; 3 = mucous membrane pemphigoid-like type; 4 = Brunsting-Perry 
pemphigoid-like type; 5 = linear IgA dermatosis-like type; ND: not done; DIF: direct immunofluoroscence; IIF: indirect immunofluoroscence. 
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was gradually increased up to 100 mg/day as tolerated. For 
colchicine, patients were maintained on a dose of 1.2 mg/day. 
Other immunosuppressive medications, such as cyclophospha-
mide, mycophenolate mofetil, cyclosporine and azathioprine, 
were considered if patients did not respond to the combination 
therapy of methylprednisolone, dapsone and colchicine. 
To assess the relationship between systemic corticosteroid 
dose and therapeutic efficacy, we stratified the patients into 
two groups: a high-dose steroid (HDS) group that received 
> 8 mg/day of methylprednisolone for at least one month; and 
a low-dose steroid (LDS) group that received ≤ 8 mg/day of 
methylprednisolone for at least one month. We performed a 
subset analysis of 19 patients with EBA treated with methyl-
prednisolone, dapsone and colchicine by a single physician. 
Patients who were prescribed other immunosuppressive agents, 
including systemic corticosteroid pulse therapy, cyclophospha-
mide, mycophenolate mofetil, cyclosporine or azathioprine, 
were excluded from this subgroup.
Baseline characteristics were summarized by EBA type using 
descriptive statistics. All descriptive summaries are presented 
with a median and range for continuous variables and a count 
and percentage for categorical variables. Fisher’s exact test 
and Wilcoxon rank-sum test were performed to compare the 
clinical features between two groups (classic vs. BP-like type 
and HDS vs. LDS group). Comparison of time to remission 
was done by log-rank test. All analyses were performed with 
SAS (version 9.1, SAS institute, North Carolina, USA) using 
an alpha level of 0.05.
RESULTS
In our cohort, the median age at disease onset was 
44.0 (range 21–79) years, with 14 (46.7%) male pa-
tients and 16 (53.3%) female patients. The median 
length of follow-up period was 23.0 (range 0.3–155) 
months. Classification by clinical phenotype revealed 
11 (36.7%) individuals with classic, 14 (46.7%) with 
BP-like, 2 (6.7%) with MMP-like, 2 (6.7%) with 
Brunsting-Perry pemphigoid-like, and 1 (3.3%) with 
LAD-like type. The clinical features of the varying 
EBA patient types are shown in Table III. No signi-
ficant differences were identified between patients 
with classic and BP-like types in terms of sex (male 
36.4% vs. 50%, p = 0.6887), age of onset (median 
age 58.0 years vs. 43.0 years, p = 0.2721), duration 
of follow-up (median duration 25.0 vs. 23.0 months, 
p = 0.7571), maximum methylprednisolone dose over 
a one-month period (median dose 8.0 vs. 16.0 mg, 
p = 0.5149) and oral involvement (7 of 11 patients vs. 
6 of 14 patients). 
All patients were initially treated with combination 
therapy of methylprednisolone, dapsone and colchicine. 
Other immunosuppressive therapies, including cyclop-
hosphamide, mycophenolate mofetil, cyclosporine or 
azathioprine, were prescribed for 6 (20%) patients who 
did not respond to the initial regimen (Table IV). Treat-
ment was well tolerated in most patients, with the excep-
tion of one 37-year-old patient who developed a cataract 
after 10 years of corticosteroid therapy. After analyzing 
our database, the following diseases were considered 
as co-morbid disease associated with EBA: 3 patients 
with diabetes mellitus, two patients with systemic lupus 
erythematosus. Another patient died approximately one 
year after diagnosis as a result of an esophageal stricture 
secondary to mucosal involvement.
The median time to remission for the 30 patients 
with EBA was 9 months. From a cross-sectional point 
of view, complete remission was observed in 33.3% 
of individuals (8/24), and partial remission in 20.8% 
(5/24) at one year after treatment initiation. Complete 
remission was achieved in 33.3% (5/15) of patients at 3 
years after diagnosis, and 45.5% (5/11) at 6 years after 
diagnosis. Partial remission was seen in 33.3% of indivi-
duals (5/15) at 3 years after diagnosis and 45.5% (5/11) 
at 6 years after diagnosis (Fig. 1). We also compared 
median time to remission between patients with classic 
EBA (n = 11) and BP-like EBA (n = 14). The median time 
to remission was 10 months in classic patients with EBA 
and 18 months in BP-like patients with EBA (Table II). 
No statistical differences were identified between two 
types in time to remission (p = 0.3367) and complete 
remission (p = 0.9431) (Fig. 2). 
According to the treatment dosage of methylpredni-
solone, patients were stratified into the HDS group (6 
patients), and the LDS group (13 patients). The resulting 
Kaplan–Meier curves demonstrate that significantly 
better responses to treatment were achieved in the HDS 
group irrespective of clinical types. The median time 
to remission was 3 months in the HDS group and 12 
months in LDS group (p = 0.003) (Fig. 3).
Table III. Clinical features of epidermolysis bullosa acquisita (EBA) patients. No statistical differences were observed in age, sex, maximal 
dose of corticosteroid or oral involvement between classic and bullous pemphigoid (BP)-like EBA
Clinical type
Classic BP-like MMP-like
Brunsting-Perry 
pemphigoid-like LAD-like Total
Number of patients (M/F) 11 (4/7) 14 (7/7) 2 (1/1) 2 (1/1) 1 (1/0) 30 (14/16) 
Median age of onset, years (range) 58.0 (21–79) 43.0 (28–67) 56.5 (49–64) 24.5 (24–25) 28.0 44.0 (21–79)
Median follow-up duration, months (range) 25.0 (1–96) 23.0 (0.3–155) 86.5 (21–152) 20.5 (13–28) 10.0 23.0 (0.3–155)
Maximum dose of MPD at least 1 month, mg (range) 8.0 (0–48) 16.0 (4–72) 8.0 2.0 (0–4) 16.0 8.0 (0–72)
Oral involvement, n (%) 7 (63.6) 6 (42.9) 2 (100) 0 0 15 (50)
Time to remissiona, months, n 10 18
aComplete remission plus partial remission. 
MMP: mucous membrane pemphigoid; LAD: linear IgA bullous dermatosis; MPD: methylprednisolone.
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DISCUSSION
Our results show that the classic and BP-like presen-
tations are the two most common clinical types of 
this disease. In our cohort, generalized inflammatory 
BP-like EBA was slightly more common than the 
classic form, which primarily affects trauma-prone 
extensor skin surfaces. No comparisons between the 
other subtypes, including MMP-like, Brunsting-Perry 
pemphigoid-like, and LAD-like EBA, could be made 
due to the small number of patients in our cohort. We 
did not find the classic type to be statistically different 
from the BP-like type in terms of age of onset, sex, 
maximum prescribed dose of systemic corticosteroids 
and oral involvement.
In our clinic, we used a combination of a low-dose 
systemic steroids, dapsone, and colchicine as a first-line 
therapy. Colchicine is often used as a first-line drug 
because of its low incidence of serious side-effects (11), 
and, in this study, all patients were prescribed colchicine 
at a dose of 1.2 mg/day. Dapsone is another safe and ef-
fective medication used in the treatment of EBA (10). In 
this study, all patients with EBA were initially prescribed 
dapsone at a dose of 25 mg/day, which was gradually 
increased up to 100 mg/day as tolerated. Although some 
previous reports recommend the use of high-dose syste-
mic corticosteroids in EBA (19, 20), we use relatively low 
doses (8 mg for the classic type and 16 mg for BP-like 
type as median maximum methylprednisolone doses) to 
avoid the side-effects often associated with long-term 
corticosteroid use. Notably, we were able to achieve fa-
vorable outcomes (9 months of time to remission) without 
serious side-effects with this regimen. 
Although some data has linked EBA with inflam-
matory bowel disease (IBD) (21–23), none of the pa-
tients in our cohort had EBA with comorbid IBD. The 
incidence and prevalence of IBD in Korea are lower 
than that in North America and Europe, although they 
are increasing. In addition, IBD patients in Korea are 
associated with different genomics from those in Wes-
tern countries (24). These reasons may explain the low 
incidence of IBD among our patients with EBA. Also, 
EBA has been reported to be associated with systemic 
diseases, including rheumatoid arthritis, diabetes mel-
litus, cryoglobulinaemia, psoriasis and systemic lupus 
erythematosus (9, 25). There were three patients with 
diabetes mellitus and two with systemic lupus erythe-
matosus in our study. The most severe complication 
Table IV. Six patients who were treated with other immunosuppressive drugs
Pat. No.
Sex/age 
(years)
Clinical 
types Immunosuppressive drugs
Duration of treatment 
before the beginning of 
other immunosuppressive 
drugs
Remission 
time
1 F/78 Classic Methylprednisolone pulse therapy (methylprednisolone 500 mg for 3 days) 1 month 3 months
3 F/37 Classic Mycophenolate mofetil 2000 mg
Methylprednisolone pulse therapy (methylprednisolone 500 mg for 3 days)
1 month 10 months
13 F/45 BP-like Mycophenolate mofetil 1500 mg
Pulse therapy with methylprednisolone and cyclophosphamide 
(methylprednisolone 500 mg for 3 days and cyclophosphamide 500 mg for 1 day)
36 months 72 months
17 M/39 BP-like Cyclosporine 100 mg 30 months 63 months
25 M/55 BP-like Azathioprine 100 mg 1 month No remission
26 F/66 MMP-like Pulse therapy with methylprednisolone and cyclophosphamide 
(methylprednisolone 500 mg for 3 days and cyclophosphamide 500 mg for 1 day)
1 month 23 months
BP: bullous pemphigoid; MMP: mucous membrane pemphigoid.
Fig. 1. Time to remission for 30 patients with epidermolysis bullosa acquisita (EBA). (A) Kaplan–Meier curve of remission in EBA. Median time to remission 
was 9 months. (B) Cumulative remission rate of patients with EBA by treatment duration. One year after therapy initiation, partial remission (PR) was achieved 
in 20.8% (5/24 patients) and complete remission (CR) in 33.3% (8/24 patients). 
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that developed in our patients with EBA was esopha-
geal stricture, which correlated with severe mucosal 
involvement (26). Other minor common problems were 
secondary skin infections, milia, scarring and fibrosis. 
We also compared the demographics and clinical 
course of classic EBA with BP-like EBA. The classic 
presentation appears to convey a more favorable out-
come, with faster median times to remission than the 
BP-like presentation. However, we did not find any 
statistical differences between the two types. 
In our comparison of the groups treated with low- and 
high-dose systemic corticosteroids, we were unable 
to identify any differences in baseline demographics, 
including sex ratio, clinical types and median age of 
onset (Table V). However, the HDS group did show 
significantly shorter times to remission compared with 
the LDS group, irrespective of clinical type. Moreover, 
while the clinical disease activity of the HDS group was 
more severe at baseline, relatively better outcomes were 
nevertheless achieved in this group. These data suggest 
that higher doses of systemic corticosteroids (specifi-
cally > 8 mg/day of methylprednisolone) not only treat 
Table V. Demographics by high-dose steroid (HDS) and low-dose 
steroid (LDS) group. No statistical differences were observed in 
sex, clinical types, or age of onset between the HDS and LDS group 
(p = 1.0000, 0.7147 and 0.6807 for each variable)
LDS group HDS group p-value
Male to female ratio 6:7 2:4 1.0000
Clinical type, n (%)
Classic 5 (71.4) 2 (28.6) 0.7147
BP-like 5 (62.5) 3 (37.5)
MMP-like 1 (100) 0 (0)
Brunsting-Perry 
pemphigoid-like 2 (100) 0 (0)
LAD-like 0 (0) 1 (100)
Age at onset, years, 
median (min, max)
44.0 (21.0, 79.0) 37.5 (28.0, 61.0) 0.6807
Time to remission, months 12 3 0.0030
BP: bullous pemphigoid; MMP: mucous membrane pemphigoid; LAD: linear 
IgA bullous dermatosis.
Fig. 3. Comparison of time to remission between high-dose steroid (HDS) and 
low-dose steroid (LDS) group (n = 19). A HDS group (n = 6) demonstrated better 
outcomes than a comparable LDS group (n = 13) (3 months vs. 12 months, 
p = 0.003). High dose: > 8 mg of methylprednisolone for at least one month; 
low dose: ≤ 8 mg of methylprednisolone for at least one month.
Fig. 2. Comparison of time to remission between classic and bullous pemphigoid (BP)-like epidermolysis bullosa acquisita (EBA) (n = 25). (A) Kaplan–Meier 
curve of remission (partial remission (PR) plus complete remission (CR)) in two different types: classic and BP-like type. No statistical differences were 
identified in the time to remission between classic (n = 11) and BP-like (n = 14) EBA (10 months vs. 18 months, p = 0.3367). (B) Kaplan–Meier curve of CR 
showed that there were no statistical differences in the time to CR between classic and BP-like EBA (p = 0.94). (C), (D) Cumulative remission rate of classic 
and BP-like type by treatment duration. Rates of PR and CR between classic and BP-like type were assessed after the first year of treatment (PR; 11.1% vs. 
30% CR; 44.4% vs. 20%) and the third year of treatment (PR; 50% vs. 50% CR; 50% vs. 33.3%). Time to CR was not different between classic and BP-like 
types (p = 0.9431). 
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patients with EBA more effectively, but also expedite 
the time to remission. 
In conclusion, the median time to remission for EBA 
was 9 months in our cohort. No significant differences 
were identified between classic-type and BP-like type 
EBA in terms of age of onset, sex, treatment intensity, 
median time to remission and oral involvement. A group 
of patients treated with higher doses of corticosteroids 
(> 8 mg/day of methylprednisolone for at least one month) 
showed more favorable outcomes than individuals treated 
with lower doses of corticosteroids (≤ 8 mg/day of 
methylprednisolone for at least one month).
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